Want to see AZTR full AI Analyst Report?
Azitra Inc (AZTR) Risk Analysis
Risk Overview Q2, 2026
Source: the company's latest filing for the period ended Jun 30, 2026, filed Aug 12, 2026
Risk Change Over Time
- Share Price & Shareholder Rights - Risk 1Our outstanding warrants and options are exercisable for a number of shares of common stock that substantially exceeds the number of shares of our common stock currently outstanding, and future exercises, sales and other issuances of our common stock could result in substantial dilution to our stockholders and could cause the market price of our common stock to decline.
As of June 30, 2026, we had 60,603,742 shares of common stock outstanding, and there were outstanding warrants to purchase an aggregate of 219,470,313 shares of common stock, including pre-funded warrants to purchase 42,411,822 shares of common stock at an exercise price of $0.0001 per share and Series B Warrants and Series C Warrants to purchase an aggregate of 168,846,252 shares of common stock at an exercise price of $0.123 per share, as well as outstanding options to purchase 651,871 shares of common stock. The exercise of outstanding warrants and options, sales under the ELOC and other issuances of equity or equity-linked securities would dilute, in some cases substantially, the ownership interests of our existing stockholders. In addition, substantially all of the shares of common stock issuable upon exercise of our outstanding warrants have been, or are required to be, registered for resale under the Securities Act, and sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could cause the market price of our common stock to decline and could impair our ability to raise capital through future sales of equity securities. The exercise price of the Series C Warrants is also subject to a downward reset in certain circumstances described in Note 6 to our unaudited condensed financial statements included elsewhere in this report, which could result in issuances of common stock at prices below the current exercise price.
- Share Price & Shareholder Rights - Risk 2We are not in compliance with the NYSE American continued listing standards. If we are unable to regain compliance within the applicable plan period, or thereafter fail to maintain compliance, the NYSE American may delist our common stock, which would adversely affect the market price and liquidity of our common stock and our ability to raise capital.
As described elsewhere in this report, on October 1, 2025 and March 13, 2026, we received deficiency letters from the NYSE American with respect to the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii), respectively, of the NYSE American Company Guide. The NYSE American accepted our plan of compliance and granted a plan period through April 1, 2027, during which we must make progress consistent with the plan and provide quarterly updates to the NYSE American staff. Although our stockholders' equity as of June 30, 2026 was approximately $7.3 million, which exceeds the applicable minimum stockholders' equity requirements, any determination that we have regained compliance will be made by the NYSE American, and we expect to continue to incur net losses, which could cause our stockholders' equity to again fall below the applicable requirements. If we fail to regain compliance by the end of the plan period, fail to make progress consistent with the plan or otherwise fail to comply with the NYSE American's continued listing standards (including as a result of a low selling price of our common stock), the NYSE American may commence delisting proceedings. Delisting would likely reduce the liquidity and market price of our common stock, reduce the number of investors willing or permitted to hold our common stock and impair our ability to raise capital, including under the ELOC and our existing registration statements.
Risk Highlights Q2, 2026
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 47
- Share Price & Shareholder Rights - Risk 1AddedOur outstanding warrants and options are exercisable for a number of shares of common stock that substantially exceeds the number of shares of our common stock currently outstanding, and future exercises, sales and other issuances of our common stock could result in substantial dilution to our stockholders and could cause the market price of our common stock to decline.
As of June 30, 2026, we had 60,603,742 shares of common stock outstanding, and there were outstanding warrants to purchase an aggregate of 219,470,313 shares of common stock, including pre-funded warrants to purchase 42,411,822 shares of common stock at an exercise price of $0.0001 per share and Series B Warrants and Series C Warrants to purchase an aggregate of 168,846,252 shares of common stock at an exercise price of $0.123 per share, as well as outstanding options to purchase 651,871 shares of common stock. The exercise of outstanding warrants and options, sales under the ELOC and other issuances of equity or equity-linked securities would dilute, in some cases substantially, the ownership interests of our existing stockholders. In addition, substantially all of the shares of common stock issuable upon exercise of our outstanding warrants have been, or are required to be, registered for resale under the Securities Act, and sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could cause the market price of our common stock to decline and could impair our ability to raise capital through future sales of equity securities. The exercise price of the Series C Warrants is also subject to a downward reset in certain circumstances described in Note 6 to our unaudited condensed financial statements included elsewhere in this report, which could result in issuances of common stock at prices below the current exercise price.
- Share Price & Shareholder Rights - Risk 2AddedWe are not in compliance with the NYSE American continued listing standards. If we are unable to regain compliance within the applicable plan period, or thereafter fail to maintain compliance, the NYSE American may delist our common stock, which would adversely affect the market price and liquidity of our common stock and our ability to raise capital.
As described elsewhere in this report, on October 1, 2025 and March 13, 2026, we received deficiency letters from the NYSE American with respect to the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii), respectively, of the NYSE American Company Guide. The NYSE American accepted our plan of compliance and granted a plan period through April 1, 2027, during which we must make progress consistent with the plan and provide quarterly updates to the NYSE American staff. Although our stockholders' equity as of June 30, 2026 was approximately $7.3 million, which exceeds the applicable minimum stockholders' equity requirements, any determination that we have regained compliance will be made by the NYSE American, and we expect to continue to incur net losses, which could cause our stockholders' equity to again fall below the applicable requirements. If we fail to regain compliance by the end of the plan period, fail to make progress consistent with the plan or otherwise fail to comply with the NYSE American's continued listing standards (including as a result of a low selling price of our common stock), the NYSE American may commence delisting proceedings. Delisting would likely reduce the liquidity and market price of our common stock, reduce the number of investors willing or permitted to hold our common stock and impair our ability to raise capital, including under the ELOC and our existing registration statements.
- Share Price & Shareholder Rights - Risk 3The market price of our shares may be subject to fluctuation and volatility. You could lose all or part of your investment.
The market price of our common stock is subject to wide fluctuations in response to various factors, some of which are beyond our control. Since shares of our common stock were sold in our initial public offering, or IPO, in June 2023 at a price of $999.00 per share, the reported high and low sales prices of our common stock have ranged from $1,034.96 to $0.17 through February 26, 2026. The market price of our shares on the NYSE American may fluctuate as a result of a number of factors, some of which are beyond our control, including, but not limited to: - actual or anticipated variations in our and our competitors' results of operations and financial condition;- changes in earnings estimates or recommendations by securities analysts, if our shares are covered by analysts;- market acceptance of our product candidates;- development of technological innovations or new competitive products by others;- announcements of technological innovations or new products by us;- publication of the results of preclinical or clinical trials for our product candidates;- failure by us to achieve a publicly announced milestone;- delays between our expenditures to develop and market new or enhanced products and the generation of sales from those products;- developments concerning intellectual property rights, including our involvement in litigation brought by or against us;- regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified products;- changes in the amounts that we spend to develop, acquire or license new products, technologies or businesses;- changes in our expenditures to promote our product candidates;- our sale or proposed sale, or the sale by our significant stockholders, of our shares or other securities in the future;- changes in key personnel;- success or failure of our research and development projects or those of our competitors;- the trading volume of our shares; and - general economic and market conditions and other factors, including factors unrelated to our operating performance. These factors and any corresponding price fluctuations may materially and adversely affect the market price of our shares and result in substantial losses being incurred by our investors. In the past, following periods of market volatility, public company stockholders have often instituted securities class action litigation. If we were involved in securities litigation, it could impose a substantial cost upon us and divert the resources and attention of our management from our business.
- Share Price & Shareholder Rights - Risk 4Our failure to meet the continued listing requirements of the NYSE American could result in a delisting of our common stock.
On October 1, 2025, we received written notification from the NYSE American that we are not in compliance with Section 1003(a)(ii) (the "Deficiency Letter") of the NYSE American Company Guide (the "Company Guide"). The Company has submitted a plan (the "Plan") to regain compliance to the NYSE American and on December 16, 2025, received notice that the NYSE American had accepted the Company's Plan to regain compliance and granted a plan period through April 1, 2027 (the "Plan Period Deadline"). If the Company does not regain compliance with the NYSE American continued listing standards by the Plan Period Deadline, or if the Company does not make progress consistent with its Plan during the plan period, then the NYSE American may initiate delisting proceedings. Additionally, if we fail to satisfy the continued listing requirements of the NYSE American, including the corporate governance requirements or the minimum closing bid price requirement, the NYSE American may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the NYSE American's minimum bid price requirement or prevent future non-compliance with the NYSE American's listing requirements.
- Share Price & Shareholder Rights - Risk 5Shares eligible for future sale may adversely affect the market for our common stock.
As of the date of this report, we have 16,192,438 shares of common stock issued and outstanding, all of which are eligible for sale by means of ordinary brokerage transactions in the open market pursuant to Rule 144, promulgated under the Securities Act, subject to certain limitations under Rule 144. Any substantial sale of our common stock pursuant to Rule 144 or pursuant to any resale report may have a material adverse effect on the market price of our common stock.
- Share Price & Shareholder Rights - Risk 6We are an "emerging growth company" under the JOBS Act and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.
We are an "emerging growth company," as defined in the JOBS Act and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not "emerging growth companies" including, but not limited to: - not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;- reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements;- exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments; and - extended transition periods available for complying with new or revised accounting standards. We have chosen to take advantage of all of the benefits available under the JOBS Act, including the exemptions discussed above. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We will remain an "emerging growth company" for up to five years, although we will lose that status sooner if our revenues exceed $1.235 billion, if we issue more than $1 billion in non-convertible debt in a three-year period, or if the market value of our common stock that is held by non-affiliates exceeds $700 million as of June 30 in any future year.
- Share Price & Shareholder Rights - Risk 7Our charter documents and Delaware law may inhibit a takeover that stockholders consider favorable.
Provisions of our amended and restated certificate of incorporation and amended and restated bylaws and applicable provisions of Delaware law may delay or discourage transactions involving an actual or potential change in control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. The provisions in our amended and restated certificate of incorporation and amended and restated bylaws: - limit who may call stockholder meetings;- restrict our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed;- do not provide for stockholder action by written consent;- do not provide for cumulative voting rights; and - provide that all board vacancies may be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum. Section 203 of the DGCL may limit our ability to engage in any business combination with a person who beneficially owns 15% or more of our outstanding voting stock unless certain conditions are satisfied. This restriction lasts for a period of three years following the share acquisition. These provisions may have the effect of entrenching our management team and may deprive you of the opportunity to sell your shares to potential acquirers at a premium over prevailing prices. This potential inability to obtain a control premium could reduce the price of our common stock.
- Share Price & Shareholder Rights - Risk 8If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our shares, the price of our shares could decline.
The trading market for our shares will rely in part on the research and reports that equity research analysts publish about us and our business, if at all. We do not have control over these analysts and we do not have commitments from them to write research reports about us. The price of our shares could decline if no research reports are published about us or our business, or if one or more equity research analysts downgrades our shares or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business.
- Share Price & Shareholder Rights - Risk 9We have and will continue to incur significant increased costs as a result of being a public company that reports to the SEC and our management will be required to devote substantial time to meet compliance obligations.
As a public company reporting to the SEC, we will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to reporting requirements of the Exchange Act and the reporting and governance provisions of the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Protection Act, as well as rules subsequently implemented by the SEC, that impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. There are significant corporate governance and reporting provisions in these laws that will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and may also place undue strain on our personnel, systems and resources. Our management and other personnel will need to devote a substantial amount of time to these regulations. In addition, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our Board our Board committees or as executive officers.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.